Intravesical BCG Induces CD4⁺ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

ABSTRACT: Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is the standard of care in treating non-muscle-invasive bladder cancer, yet its mechanism of action remains elusive. Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4⁺ T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized. We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer. Our data demonstrate that cancer progression in the N-methyl-N-nitrosourea (MNU) rat model of bladder cancer was characterized by a decline in the CD8/FoxP3 ratio, consistent

SUBMITTER: Kates M 

PROVIDER: S-EPMC5536898 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature